Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Medová

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Trends in Cell Biology|September 3, 2022
Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteinsAdam Zabini, Yitzhak Zimmer, Michaela Medová
Frontiers in Oncology|November 5, 2019
A Comparative Analysis of Individual RAS Mutations in Cancer BiologyCarmen Muñoz-Maldonado, Yitzhak Zimmer, Michaela Medová
BMC Bioinformatics|November 11, 2019
ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic dataMatúš Medo, Daniel M Aebersold, Michaela Medová
International Journal of Cancer|March 15, 2011
MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaksMichaela Medová, Daniel M Aebersold, Yitzhak Zimmer
Biochemical Pharmacology|August 31, 2016
Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancerPaola Francica, Daniel M Aebersold, Michaela Medová
Cancers|January 1, 2014
The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical AspectsMichaela Medová, Daniel M Aebersold, Yitzhak Zimmer
Nature Communications|November 2, 2024
A comprehensive comparison of tools for fitting mutational signaturesMatúš Medo, Charlotte K Y Ng, Michaela Medová
International Journal of Radiation Oncology, Biology, Physics|August 27, 2022
Parameters of the Lyman Model for Calculation of Normal-Tissue Complication Probability: A Systematic Literature ReviewFabio Dennstädt, Michaela Medová, Paul Martin Putora, et al.
Cancer Letters|December 15, 2018
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinaseEleonora Orlando, Daniel Matthias Aebersold, Michaela Medová, et al.
Molecular Cancer|February 20, 2018
The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancerMichaela Poliaková, Daniel M Aebersold, Yitzhak Zimmer, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Trends in Cell Biology|September 3, 2022
Beyond keratinocyte differentiation: emerging new biology of small proline-rich proteinsAdam Zabini, Yitzhak Zimmer, Michaela Medová
Frontiers in Oncology|November 5, 2019
A Comparative Analysis of Individual RAS Mutations in Cancer BiologyCarmen Muñoz-Maldonado, Yitzhak Zimmer, Michaela Medová
BMC Bioinformatics|November 11, 2019
ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic dataMatúš Medo, Daniel M Aebersold, Michaela Medová
International Journal of Cancer|March 15, 2011
MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaksMichaela Medová, Daniel M Aebersold, Yitzhak Zimmer
Biochemical Pharmacology|August 31, 2016
Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancerPaola Francica, Daniel M Aebersold, Michaela Medová
Cancers|January 1, 2014
The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical AspectsMichaela Medová, Daniel M Aebersold, Yitzhak Zimmer
Nature Communications|November 2, 2024
A comprehensive comparison of tools for fitting mutational signaturesMatúš Medo, Charlotte K Y Ng, Michaela Medová
International Journal of Radiation Oncology, Biology, Physics|August 27, 2022
Parameters of the Lyman Model for Calculation of Normal-Tissue Complication Probability: A Systematic Literature ReviewFabio Dennstädt, Michaela Medová, Paul Martin Putora, et al.
Cancer Letters|December 15, 2018
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinaseEleonora Orlando, Daniel Matthias Aebersold, Michaela Medová, et al.
Molecular Cancer|February 20, 2018
The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancerMichaela Poliaková, Daniel M Aebersold, Yitzhak Zimmer, et al.
Pageof 5